https://www.selleckchem.com/pr....oducts/gi254023x.htm
Marked reduction of inflammation and fibrosis-related gene expression in the kidney was also observed. In vitro, PAR1 and PAR2 agonists additively increased mRNA expression of Mcp1 or Pai1 in human endothelial cells. Changes induced by the PAR1 agonist were blocked by a NF-κB inhibitor, whereas those of PAR2 agonist were blocked by MAPK and/or NF-κB inhibitors. These findings suggest that PAR1 and PAR2 additively contribute to DKD pathogenesis, and dual blockade of both could be a novel therapeutic option for treatment of DKD patients
Like
Comment
Share
